AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 NOV 19 - (NewsRx.com & NewsRx.net) -- The U.S. National Institutes of Health (NIH) has awarded a $19 million, 5-year grant for HIV vaccine development grant to Novavax, Inc., along with partners at Emory University School of Medicine and the Emory Vaccine Center, Tulane University, and the University of Pittsburgh.
The award is part of the National Institute of Allergy and Infectious Disease (NIAID) Vaccine Design and Development Teams program. The Emory team of researchers includes Richard W. Compans, PhD, professor and chair of microbiology and immunology and faculty members Sang-Moo Kang, PhD, Andrei N. Vzorov, PhD, and Chinglai Yang, PhD.
Scientists at Emory and Novavax, Inc., including Robin A. Robinson, PhD, director of Novavax's vaccine division and principal investigator for the grant, are developing and testing a novel virus-like particle (VLP) vaccine. The genes that encode the main structural proteins of HIV (the envelope and gag core proteins) will first be expressed in insect or mammalian cells. These proteins self-assemble to form VLPs, which are devoid of the virus genes themselves, and will be purified to form the vaccine. The investigators propose to deliver this protein-based vaccine in a manner that they predict will induce broad neutralizing antibodies against HIV in blood and mucosal tissues. The HIV genes for initial testing of the vaccine were taken from HIV strains in circulation in the United States. In subsequent studies the investigators will use genes from other geographic ...
Source: HighBeam Research, NIH-funded HIV vaccine design and development team in place.